Trastuzumab deruxtecan in HER2-positive state-of-the-art bosom cancer cells with or even without human brain metastases: a period 3b\/4 trial

.Attribute Medicine, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) treatment of people with HER2+ advanced breast cancer and also energetic or even dependable human brain metastases presented consistent intracranial task and also systemic efficacy of T-DXd.